The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Makaleler > Derleme · 2020
Yazarlar: BAKİYE GÖKER BAĞCA, Çığır BİRAY AVCI
Cytokine & Growth Factor Reviews, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2020, cilt 54, ss 51-61
DOI: 10.1016/j.cytogfr.2020.06.013
Özet
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.